All News

Increased risk of aortic regurgitation and atrial fibrillation in radiographic axSpA pts when compared to general population. No significant risk for AV block (II-III). Unclear if treatment affects cardiac risk in these patients. @RheumNow #EULAR2022 ABST#POST0146

COVID-19 mostly mild for majority of SpA patients. Steroid use associated with more severe COVID-19 outcomes (OR 3.15). TNFi found to be protective! (OR 0.26) @RheumNow #EULAR2022 ABST#OP0254

Perrot et al. Factors assoc severe COVID in SpA. corticosteroid intake (3.15 [1.46-6.76]), age (OR=1.06 [1.04-1.08]) while anti-TNF (OR=0.26 [0.09-0.78]) was protective @RheumNow #EULAR2022 OP0254 https://t.co/bIiEW6efQ2

EULAR Abstract Archive

#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH

Ok to taper? In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering. 69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months. Taper group did use more NSAIDs, cDMARDs, steroids @RheumNow #EULAR2022 ABST#OP0261

Pregnancy data in SpA from 122 pts 40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial dz 7 pts required start of TNFi during 2nd or 3rd trimester 40% post-partum @RheumNow #EULAR2022 ABST#POST0151 https://t.co/cdFRhRuCVH

SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn

The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al

#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

#OP0248 #EULAR2022 In contrast to data from #OP0247 where SpA was protective, a matched population study in Canada found the opposite - increased risk of hospitalisation & death in SpA. A meta-analysis cd help to disentangle this @RheumNow https://t.co/keNZ2RPnXF

WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022 https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH

https://bit.ly/3MbzRcJ

What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn

Women with spondyloarthritis at increased risk of gestational diabetes, elective and emergency C-sections, and spontaneous pre-term birth. Infants were not more likely to be born SGA. @RheumNow #EULAR2022 ABST#OP0126 https://t.co/BTXQqruvPs

Differentiating AS from OCI using CT scanning by Terrier et al showed that Subchondral Bone Attenuation Coefficient (SBAC) was higher in OCI than AS with a threshold of >7500 Hounslow Units discriminating the two conditions #EULAR2022 @RheumNow POS0126 https://t.co/8MdSe3Dqp7

GM-CSF increased in patients with active ankylosing spondylitis, correlates with disease activity, not duration. TNFi does not affect GM-CSF levels. Could explain efficacy of JAKinibs and response for residual inflammation during TNF blockade. @RheumNow #EULAR2022 ABST#OP0107

Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat . Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw

JAKi for nonradiographic axSpA One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. And the question of the utility of JAK inhibitors for the treatment of axSpA has been on the rise. https://t.co/xq8ICyKKv0 https://t.co/o2iUgyU60A

https://bit.ly/3PZZccS

💫Trajectory analysis in SpA💫 Data on 1,125 patients Prediction of spinal radiographic progression ⭐️FAST associated w/ onset at older age & 👁involvement ⭐️SLOW progression associated w/ female gender & peripheral involvement. #EULAR2022 @RheumNow OP0151 https://t.co/E80qCLEtBv

Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and hypertension clusters assoc worse disease activity and function @RheumNow #EULAR2022 OP0154 https://t.co/jGQXayAYs9 https://t.co/SnVDhVYQq5

EULAR Abstract Archive

#EULAR2022 ASAS/EULAR AxSpA Recs ⭐️Last: 2016 ▶️All: education, exercise, 🚭 ▶️❌csDMARD for axial disease ▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1 ▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17 ▶️Sustained remission: tapering of bDMARD "can be considered" @RheumNow https://t.co/3yYU0Vb37r

Topics

All News

Do you get our email newsletter?